The off-the-shelf packaging plasmids will also support the development of cell and gene therapies by offering quick availability, lowered development costs, and simplified supply chains
Charles River launches off-the-shelf LVV packaging plasmids. (Credit: National Cancer Institute on Unsplash)
Charles River Laboratories has introduced its off-the-shelf lentiviral vector (LVV) packaging plasmids to address the challenges related to plasmid sourcing in cell and gene therapies with a streamlined solution.
The new plasmids are expected to expedite and standardise the development of lentiviral vectors from the clinical to the commercial production phase.
Charles River’s off-the-shelf packaging plasmids will also support the development of cell and gene therapies by offering quick availability, lowered development costs, and simplified supply chains. This streamlines and secures the production of the lentiviral vector.
The pharmaceutical company offers services to address the demands of its customers, such as regulatory requirements or product qualities, in addition to its off-the-shelf options.
These include services for the creation of viral vectors for use in clinical studies or for commercial purposes, spanning from clone creation to good manufacturing practice (GMP).
Charles River biologics solutions corporate SVP Kerstin Dolph said: “We are thrilled to announce this addition to our product offering.
“Our LVV packaging plasmids allow us to further support advanced therapy programs and most importantly, help expedite the delivery of safe, effective therapies to those who need them most.”
The pharmaceutical company said that the addition of off-the-shelf LVV plasmids follows the introduction of the pHelper plasmids and eXpDNA plasmid manufacturing platform.
Charles River recently expanded its cell and gene therapy portfolio and made multiple acquisitions to streamline complex supply chains and meet the rising global demand for plasmid DNA, viral vector, and cell therapy services.
The company also offers support and supply chain simplification to those creating cell and gene therapies.
Recently, the pharmaceutical firm collaborated with South Korean biotechnology company Curigin to produce oncolytic ribonucleic acid interference (RNAi) gene therapies including adenoviral vector.
Under the collaboration, Curigin will use Charles River’s expertise in contract development and manufacturing organisation solutions to aid its preclinical and clinical trials.